Ignite Creation Date:
2025-12-25 @ 5:04 AM
Ignite Modification Date:
2026-03-01 @ 6:10 AM
Study NCT ID:
NCT05589818
Status:
RECRUITING
Last Update Posted:
2025-06-25
First Post:
2022-09-26
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Pembrolizumab for Advanced NSCLC and PS 2-3
Sponsor:
Icahn School of Medicine at Mount Sinai
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2023-05-26
Start Date Type:
ACTUAL
Primary Completion Date:
2027-05
Primary Completion Date Type:
ESTIMATED
Completion Date:
2028-05
Completion Date Type:
ESTIMATED
First Submit Date:
2022-09-26
First Submit QC Date:
None
Study First Post Date:
2022-10-21
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-06-19
Last Update Post Date:
2025-06-25
Last Update Post Date Type:
ACTUAL